Evidence map›Paper›PMID 42241713›Full record

ArticleInternal medicine journal2026

Idiopathic Pulmonary Fibrosis update, comparing the Australasian Interstitial Lung Disease Registry to the Australian Idiopathic Pulmonary Fibrosis Registry.

Michelle Chee, Yet Hong Khor, Dan Jackson, Wendy Cooper, Jason D'Costa, Sally de Boer, Adrienne Edwards, Samantha Ellis, Eli Gabbay, Henry Gallagher and 22 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Michelle CheeDepartment of Respiratory and Sleep Medicine, Box Hill Hospital, Melbourne, Victoria, Australia.ORCID https://orcid.org/0009-0006-9008-0279
Yet Hong KhorFaculty of Medicine and Health, Monash University, Melbourne, Victoria, Australia.
Dan JacksonFaculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Wendy CooperDepartment of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Jason D'CostaFlinders Medical Centre, Adelaide, South Australia, Australia.
Sally de BoerDepartment of Respiratory Medicine, Auckland City Hospital, Auckland, New Zealand.
Adrienne EdwardsRespiratory Department, Christchurch Hospital, Christchurch, New Zealand.
Samantha EllisDepartment of Respiratory and Sleep Medicine, The Alfred Hospital, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-4807-9358
Eli GabbayDepartment of Respiratory Medicine, St John of God Subiaco Hospital, Perth, Western Australia, Australia.
Henry GallagherWaikato Hospital, Hamilton, New Zealand.
Ian GlaspoleDepartment of Respiratory and Sleep Medicine, The Alfred Hospital, Melbourne, Victoria, Australia.
Nicole GohFaculty of Medicine and Health, Monash University, Melbourne, Victoria, Australia.
Christopher GraingeDepartment of Respiratory Medicine, John Hunter Hospital, Newcastle, New South Wales, Australia.
Peter HopkinsDepartment of Respiratory Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Gregory KeirDepartment of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Benjamin KwanDepartment of Respiratory and Sleep Medicine, Sutherland Hospital, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-6352-2637
John MackintoshCentre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.
Yuben MoodleyCentre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.
Irene MooreRoyal Perth Hospital, Perth, Western Australia, Australia.
Vidya NavaratnamDepartment of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.ORCID https://orcid.org/0000-0002-2914-8012
Chong OngDepartment of Respiratory and Sleep Medicine, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
Paul ReynoldsCentre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.
Karen RoyalsThe Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
Alan TeohDepartment of Respiratory and Sleep Medicine, Westmead Hospital, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-7051-112X
Lauren TroyFaculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Elizabeth VeitchConcord Hospital, Sydney, New South Wales, Australia.
Margaret WilsherDepartment of Respiratory Medicine, Auckland City Hospital, Auckland, New Zealand.
Jeremy WrobelDepartment of Respiratory Medicine, Fiona Stanley Hospital, Perth, Western Australia, Australia.
Chris ZappalaUniversity of Queensland, Brisbane, Queensland, Australia.
Tamera CorteFaculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Francis ThienDepartment of Respiratory and Sleep Medicine, Box Hill Hospital, Melbourne, Victoria, Australia.
AILDR Steering Committee

Funding

anonymous philanthropyAustralasian Interstitial Lung Disease RegistryAustralian Idiopathic Pulmonary Fibrosis RegistryBoehringer Ingelheim International GmbHCentre of Research Excellence in Pulmonary FibrosisCSRD VA 1Lung Foundation AustraliaNHMRC 1NHMRC GNT2015613Roche and Bristol Myers Squibb
6 · The paper itself

Abstract

BACKGROUND AND

aimsReal-world evaluation of clinical characteristics and treatment profile of patients with idiopathic pulmonary fibrosis (IPF) is needed to establish areas for improvement according to evidence-based recommendations. This study evaluated the clinical characteristics and treatment profile of patients with IPF from the Australasian ILD Registry (AILDR), comparing them to the Australian IPF Registry (AIPFR) cohort, to identify differences in baseline characteristics among IPF patients treated with antifibrotics and immunosuppressants.

methodsConsecutive patients with IPF enrolled between May 2016 and December 2023 from the AILDR and data of patients enrolled in the AIPFR between 2012 and 2016 were included.

resultsA total of 842 and 647 patients with IPF were included from the AILDR and the AIPFR respectively. Both cohorts were male predominant (AILDR: 72.0%; AIPFR: 67.7%) of similar mean body mass index (AILDR: 29.2 ± 4.9 kg/m

conclusionBaseline demographics from the IPF cohorts for both AILDR and AIPFR are largely comparable, with increasing antifibrotic and decreasing use of immunosuppressants since 2016. Immunosuppressive therapy in IPF remains relatively higher than expected despite guideline recommendations.

Indexed as

Antifibrotic AgentsIdiopathic Pulmonary FibrosisImmunosuppressive AgentsRegistriesAgedAustralasiaAustraliaCohort StudiesFemaleHumansIndolesMaleMiddle AgedPyridonesAntifibrotic AgentsImmunosuppressive AgentsIndolesnintedanibpirfenidonePyridonesAustralasian interstitial lung disease registryAustralian Idiopathic pulmonary fibrosis registrybaseline characteristicsIdiopathic pulmonary fibrosistreatment profile

Identifiers

PMID42241713
PMCPMC13547915

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.